| Jul 26 |
Arrowhead Pharmaceuticals: Driving To Commercialization
|
| Jul 24 |
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
|
| Jul 1 |
ARWR: Moving Plozasiran Forward in Phase 3 CVOT…
|
| Jun 30 |
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
|
| Jun 25 |
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
|
| Jun 24 |
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
|
| Jun 24 |
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
|
| Jun 5 |
Goldman starts Arrowhead at neutral, cites RNAi portfolio validation
|
| Jun 3 |
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
|
| Jun 3 |
Arrowhead says phase 3 trial of rare metabolic disease asset plozasiran meets goals
|
